The USPSTF continues to advise against ovarian cancer screening in asymptomatic women at average risk, saying the potential harms of screening outweigh the benefits.
The NCCN has updated their treatment guidelines for NSCLC to include recommendations for BRAF mutation testing to guide therapy and a new first-line treatment option for non-squamous NSCLC.

The US Food and Drug Administration (FDA) has approved a treatment demonstrated to reduce the risk of disease recurrence in patients with early-stage, human epidermal growth factor receptor 2 (HER2)-positive breast cancer.

In patients with advanced urothelial cell and renal cell cancers, immune checkpoint inhibitors are more effective and safer than conventional second-line treatment